Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors

INIS

• radiations 55%
• carcinomas 27%
• tumors 22%
• receptors 22%
• humans 16%
• in vitro 16%
• growth factors 16%
• veins 16%
• hypoxia 16%
• in vivo 11%
• interactions 11%
• comparative evaluations 11%
• cell proliferation 11%
• mice 5%
• data 5%
• design 5%
• drugs 5%
• therapy 5%
• control 5%
• additives 5%
• kinases 5%
• investigations 5%
• reduction 5%
• blood vessels 5%
• proliferation 5%
• vessels 5%
• augmentation 5%

Medicine and Dentistry

• Motesanib 72%
• Xenograft 27%
• Head and Neck Squamous Cell Carcinoma 27%
• Neoplasm 16%
• In Vitro 16%
• Human Umbilical Vein Endothelial Cell 16%
• Cell Proliferation 11%
• Tumor Hypoxia 11%
• Receptor 5%
• Hypoxia 5%
• Combination Therapy 5%
• Signal Transduction 5%
• Tumor Xenograft 5%
• Vasculotropin 5%
• Phosphotransferase 5%
• Vascular Bundle 5%
• Vasculotropin Receptor 5%
• Parenchyma 5%
• Chemotherapeutic Agent 5%
• Vascularity 5%
• Platelet Derived Growth Factor Receptor 5%
• Drug 5%
• Vasculotropin Receptor 2 5%
• Vasculotropin Receptor 3 5%
• Vasculotropin Receptor 1 5%
• Radiation Response 5%
• Absence 5%
• Assay 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Radiation 100%
• Head and Neck Squamous Cell Carcinoma 27%
• Neoplasm 16%
• Combination Therapy 5%
• Receptor 5%
• Hypoxia 5%
• Phosphotransferase 5%
• Vasculotropin 5%
• Nude Mouse 5%
• Vasculotropin Receptor 2 5%
• Platelet Derived Growth Factor Receptor 5%
• Vasculotropin Receptor 5%
• Drug 5%
• Vasculotropin Receptor 3 5%
• Vasculotropin Receptor 1 5%
• Absence 5%